• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Rochester Medical skyrockets on $262M Bard acquisition news

Rochester Medical skyrockets on $262M Bard acquisition news

September 4, 2013 By Arezu Sarvestani

Rochester Medical skyrockets on $262M Bard acquisition news

Both C.R. Bard (NYSE:BCR) and Rochester Medical (NSDQ:ROCM) got some stock market love today after the companies signed a definitive merger agreement, but Rochester was the clear Wall Street darling with a more than 40% bump in shares by early afternoon trading.

Stewartville, Minn.-based Rochester announced this morning that its board of directors unanimously approved a $20-per-share cash acquisition by Bard, a proposal worth about $262 million in total. ROCM shares jumped from last night’s close at $13.81 to $19.95 as of about 12:30 p.m. today, a $44.5% increase. Bard got a little love of its own, with shares up 1.1% to $115.95 by midday.

The $20-per-share deal represents a 37% premium over ROCM’s average closing price during the 3 months ended Sept. 2, 2013, according to a company report. Rochester plans to encourage its shareholders to sell. If all goes as planned, the transaction should close before the end of the year.

"Our agreement with Bard represents an attractive valuation for Rochester Medical shareholders, and as an all cash offer, provides liquidity for shareholders," Rochester president & CEO Anthony Conway said in prepared remarks. "We believe the merger represents a great opportunity for the combined companies to create a broad product portfolio by offering a more comprehensive range of high-quality urological and continence care products to our customers."

Bard plans to merge Rochester with its Starnorth Acquisition Corp. subsidiary, with Rochester Medical surviving the as a wholly owned subsidiary, according to regulatory documents.

Under the terms of the agreement both Conway and Rochester product technologies vice president Philip Conway have agreed to 5-year non-competition, non-solicitation and non-disparagement covenants, starting at the consummation of the merger.

The acquisition in Bard’s 2nd multi-million-dollar deal in recent weeks. Last month Bard agreed to pay $200 million up front and another possible $80 million for Medafor and its line of anti-bleeding agents.

Filed Under: Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: C.R. Bard, Deals Roundup, Minnesota, Rochester Medical Corp.

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy